The role of miR-21 in MS varies by cell type and disease course, with upregulated expression in the CD4+ T cells of patients with relapsing–remitting MS [57], and downregulated expression in secondary progressive MS patients [58]. The gene discussed is CD4; the disease is myeloid sarcoma.